Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina · 2024
Essential role of Moringa-albumin (MA) formulation in the maintenance of complement regulatory proteins on erythrocyte (TER-119) cells in diabetic mouse models.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dwi Lestari Noviana, Agustini Sulistyo Mulyo, Dliyauddin Moh, Adharini Wahyu Isnia, Nilamsari Ruri Vivian, Widodo Nashi, Rahayu Sri, Rifa'i Muhaimin
Аннотация
AIM: To evaluate the essential role of Moringa-albumin (MA) formulation in the maintenance of complement regulatory proteins through CD55 and CD59 on erythrocyte (TER-119).
METHODS: Streptozotocin (145 mg/kg) was used to induce diabetes mice. In diabetes mellitus (DM) model mice were treated with MA formulation for 14 days at a D1 - 500 mg/kg (M) + 620 mg/kg BW (A), D2 - 1000 mg/kg (M) + 420 mg/kg (A), and D3 - 1500 mg/kg (M) + 200 mg/kg (A). On the 15th day, the mice were dissected for the isolation of their bone marrow by the flushing method. The analysis flow cytometry was performed to find out the TER-119, CD55, and CD59 expressions. The data were statistically analysed with one-way ANOVA (ρ≤ 0.05) and Tukey test using SPSS version 16 for Windows.
RESULTS: The effect of MA administration in D3 group have a significant effect on increasing the profile of erythrocytes (TER-119), compared to DM (ρ≤0.05) group (STZ Injection-no treatment), as well as CD59 expressed by erythrocytes. MA administration in D1 group and D3 group significantly increased the profile of CD55 expressed by erythrocytes compared to DM (ρ≤0.05).
CONCLUSIONS: MA formulation with D3 group (1500 mg/kg (M) + 200 mg/kg (A)) was able to maintain or control complement regulatory proteins (CD55 and CD59) on red blood cells (erythrocytes/TER-119) in DM.
METHODS: Streptozotocin (145 mg/kg) was used to induce diabetes mice. In diabetes mellitus (DM) model mice were treated with MA formulation for 14 days at a D1 - 500 mg/kg (M) + 620 mg/kg BW (A), D2 - 1000 mg/kg (M) + 420 mg/kg (A), and D3 - 1500 mg/kg (M) + 200 mg/kg (A). On the 15th day, the mice were dissected for the isolation of their bone marrow by the flushing method. The analysis flow cytometry was performed to find out the TER-119, CD55, and CD59 expressions. The data were statistically analysed with one-way ANOVA (ρ≤ 0.05) and Tukey test using SPSS version 16 for Windows.
RESULTS: The effect of MA administration in D3 group have a significant effect on increasing the profile of erythrocytes (TER-119), compared to DM (ρ≤0.05) group (STZ Injection-no treatment), as well as CD59 expressed by erythrocytes. MA administration in D1 group and D3 group significantly increased the profile of CD55 expressed by erythrocytes compared to DM (ρ≤0.05).
CONCLUSIONS: MA formulation with D3 group (1500 mg/kg (M) + 200 mg/kg (A)) was able to maintain or control complement regulatory proteins (CD55 and CD59) on red blood cells (erythrocytes/TER-119) in DM.